Your browser doesn't support javascript.
loading
Clinical Course of Bio Naive Ulcerative Colitis Patients Five Years After Initiation of Adalimumab in a Nationwide Cohort.
Sundararajan, Ramaswamy; Patel, Manthankumar; Bahirwani, Janak; Trivedi, Chinmay; Mahmud, Nadim; Khan, Nabeel.
Afiliación
  • Sundararajan R; Department of Gastroenterology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA, USA.
  • Patel M; Department of Gastroenterology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA, USA.
  • Bahirwani J; Department of Gastroenterology, St. Luke's University Health Network, Bethlehem, PA, USA.
  • Trivedi C; Department of Internal Medicine, Hackensack Meridian Health - Palisades Medical Center, North Bergen, NJ, USA.
  • Mahmud N; Department of Gastroenterology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA, USA.
  • Khan N; Division of Gastroenterology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
Crohns Colitis 360 ; 6(3): otae046, 2024 Jul.
Article en En | MEDLINE | ID: mdl-39188766
ABSTRACT

Background:

There is limited data on the long-term clinical outcomes of bio-naïve ulcerative colitis (UC) patients who are initiated on adalimumab (ADA). Our study aims to evaluate the clinical course of a nationwide cohort of bio naïve UC patients who were started on ADA, and then followed for 5 years after initiation of the drug.

Methods:

We conducted a retrospective cohort study using the US Veteran Affairs Healthcare System (VAHS). Bio naïve UC patients were followed for 5 years after initiation of ADA. The primary outcome was to determine the time to discontinuation of ADA and if patients achieved endoscopic remission by the end of follow-up.

Results:

A total of 387 patients were included among whom 193 (49.87%) had pancolitis. The highest rate of ADA discontinuation was within the first year, with the elderly having a higher rate of discontinuation (HR 1.67, 95% CI 1.14-2.45) and those on concomitant immunomodulators having a lower rate of discontinuation (HR 0.70, 95% CI 0.48-1.03). In total, 125 (32.30%) patients remained on ADA at the end of their maximum follow-up. 54 (43.90%) achieved endoscopic remission.

Conclusion:

Among bio-naive UC patients who were started on ADA, a third were still on the drug at the end of 5 years and half had endoscopic remission. The rate of discontinuation was highest within the first year of initiation, but patients continued to stop the drug over the course of follow-up.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Crohns Colitis 360 Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Crohns Colitis 360 Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido